Drug Profile
PNQ 370
Alternative Names: Ado A-2A receptor antagonist - Advinus; Ado A2AR antagonist - Advinus; PNQ-370Latest Information Update: 16 Jun 2020
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antineoplastics; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Cognition disorders; Colorectal cancer; Parkinson's disease
Most Recent Events
- 16 Jun 2020 PNQ 370 is available for licensing as of 16 Jun 2020. https://impetisbiosciences.com/
- 16 Jun 2020 Pharmacodynamics data from preclinical studies in Breast and Colorectal cancers released by Impetis Biosciences
- 04 Jun 2020 PNQ 370 has patent protection in USA and Europe (Impetis Biosciences pipeline, June 2020)